{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:29:34Z","timestamp":1783034974772,"version":"3.54.6"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer (EORTC)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EORTC Breast Cancer Group"},{"name":"John Colebatch Cancer Council Victoria Fellowship"},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation, BCRF NY","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ejca.2016.11.015","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T10:10:11Z","timestamp":1482574211000},"page":"95-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Correlation between severe infection and breast cancer metastases in the EORTC 10994\/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in\u00a0breast cancer"],"prefix":"10.1016","volume":"72","author":[{"given":"Nathan","family":"Touati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tryfonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-2544","authenticated-orcid":false,"given":"Franco","family":"Caramia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bonnefoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Slaets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda S.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2016.11.015_bib1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/14737140.2016.1247698","article-title":"Targeted adjuvant therapy in breast cancer","volume":"16","author":"Zardavas","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"10.1016\/j.ejca.2016.11.015_bib2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2016.11.015_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.cr.7290309","article-title":"The host type I interferon response to viral and bacterial infections","volume":"15","author":"Perry","year":"2005","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.ejca.2016.11.015_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1470-2045(11)70094-8","article-title":"E. 1. 1.-0. S. Investiga.TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994\/BIG 1-00): a randomised phase 3 trial","volume":"12","author":"Bonnefoi","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2016.11.015_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm.1908","article-title":"A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer","volume":"15","author":"Farmer","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2016.11.015_bib6","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.11.015_bib7","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1073\/pnas.92.9.3963","article-title":"A simple p53 functional assay for screening cell lines, blood, and tumors","volume":"92","author":"Flaman","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2016.11.015_bib8","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2016.11.015_bib9","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","article-title":"Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables","volume":"26","author":"Anderson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2016.11.015_bib10","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"issue":"446","key":"10.1016\/j.ejca.2016.11.015_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2016.11.015_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2016.11.015_bib13","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2016.11.015_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2016.11.015_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/cncr.21201","article-title":"Clinical management of osteoporosis in women with a history of breast carcinoma","volume":"104","author":"Van Poznak","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2016.11.015_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.ejca.2016.11.015_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2016.11.015_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2016.11.015_bib19","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","article-title":"Impaired IFN-a production by plasmacytoid dendritic cells favors regulatory t-cell expansion that may contribute to breast cancer progression","volume":"72","author":"Sisirak","year":"2012","journal-title":"Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491632593X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491632593X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T11:53:35Z","timestamp":1536148415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491632593X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":19,"alternative-id":["S095980491632593X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.11.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between severe infection and breast cancer metastases in the EORTC 10994\/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in\u00a0breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}